Prostate cancer (PCa) is not only one of the most common, but also one of the deadliest types of cancer in men. Diagnostics are correspondingly sophisticated, from imaging via ultrasound or MRI to various biopsy techniques – often even in combination. Keep reading for current developments in early detection, staging, therapy and research.
Using AI and extensive analyses of gene activity in tumours, researchers have found new, precise biomarkers to diagnose prostate cancer at an early stage through a simple urine sample.
Soccer is not only a fun and popular sport, but can also help prevent many lifestyle-related conditions, including diabetes, heart disease, obesity, several cancers, and mental health challenges.
To diagnose prostate cancer, an MRI-guided biopsy is often performed. Now, a study shows that micro-ultrasound is just as effective, cheaper and easier to use. This could help free up MRI capacities.
Certain gene alterations can serve as a prognostic and predictive biomarker for prostate cancer. Now, researchers confirm the feasibility of using NGS on this marker for precise patient stratification and treatment selection.
Researchers have clinically validated a previously developed urine test for prostate cancer screening, which can potentially bypass invasive procedures among men who are unlikely to benefit.
Steam eliminates wrinkles and germs, but can it destroy cancer cells too? A multisite clinical trial explores the potential of a water vapor system using steam to kill prostate cancer cells.
A new study found that measuring circulating tumor cells (CTCs), rare cancer cells shed from tumors into the blood, is a reliable way to predict later treatment response and survival prospects with metastatic prostate cancer.
Certain early-stage changes to the prostate very rarely develop into aggressive cancer, but are still called that. Would it create a false sense of security to not call these “cancer” at all?
A new method of analysing the crystals in dehydrated blood could lead to a quicker, cheaper and less painful technique to diagnose, early detect, and monitor prostate cancer.
Combining risk markers, systematic evaluation of MRI images and AI, researchers aim to predict the risk of prostate cancer more accurately than before. This could save many patients from a biopsy.
The interpretation of prostate MRI is notoriously difficult. Annotating AI shows promise to help improve diagnostic performance through increased cancer detection rates with fewer false positives.
Radiotherapy of prostate cancer often comes with side effects, causing some patients to discontinue treatment. New research shows the benefits of at lowering the dose over subsequent treatment cycles.
A new study shows that extracellular vesicles shed by prostate cancer cells contain tumor-derived material that can be used as biomarkers of therapy response and resistance in metastatic disease.
US researchers have developed and validated a new urine-based test for prostate cancer, which was shown to meaningfully reduce unnecessary prostate biopsies while providing highly accurate detection.
A new SPECT/CT imaging technique using lead-212 (²¹²Pb) shows promise in targeted alpha therapy (TAT) for patients with metastatic castration-resistant prostate cancer.
A three-part ‘multiparametric’ MRI of the prostate is standard of care in the UK for patients suspected of having prostate cancer. Now, a study shows two-part scans are sufficient for diagnosis.
Prostate radiotherapy techniques have been transformed over the past two decades. One promisting technique in this context is magnetic resonance-guided radiotherapy. The latest clinical results show a dramatic reduction in side effects, improving patient outcomes and quality of life.
How often should men get checked for their level of PSA, a marker for prostate cancer? A German study involving over 12,500 men shows that a five-year interval between tests is safe.
Dutch researchers use PSMA targeting to improve detection of prostate cancer, improving nodal staging and guiding more accurate surgery for this important patient population.
